## Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K

EPIX Pharmaceuticals, Inc. Form 8-K February 22, 2007

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): <u>February 19, 2007</u> EPIX Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter) **Delaware** 

(State or Other Jurisdiction of Incorporation)

000-21863 04-3030815

(Commission File Number)

(IRS Employer Identification No.)

4 Maguire Road, Lexington, Massachusetts

02421

(Address of Principal Executive Offices)

(Zip Code)

Registrant s telephone number, including area code: (781) 761-7600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

Effective February 19, 2007, Oren Becker resigned his position as Chief Scientific Officer of EPIX Pharmaceuticals, Inc. (the Company ). The resignation as an officer will be effective immediately. The Company does not currently have any plans to replace his position. The Company and Dr. Becker have agreed that Dr. Becker will remain employed by the Company until April 19, 2007.

## Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX PHARMACEUTICALS, INC.

February 22, 2007 By: /s/ Kim C. Drapkin

Kim C. Drapkin

Chief Financial Officer